
Pamela McKay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4291708/publications.pdf Version: 2024-02-01



DAMELA MCKAV

#	Article	IF	CITATIONS
1	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 2022, 139, 2499-2511.	0.6	42
2	Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Advances, 2022, 6, 2920-2926.	2.5	20
3	Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma—ÂAll <scp>St<i>AGE</i>s</scp> : AÂconsensusâ€based position paper from the Hodgkin lymphoma subgroup of the <scp>UK</scp> National Cancer Research Institute. British Journal of Haematology, 2022. 197. 679-690.	¹ 1.2	9
4	Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a responseâ€edapted design in the firstâ€line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). British Journal of Haematology, 2021, 193, 63-71.	1.2	19
5	Central nervous system relapse of primary cutaneous CD8 + aggressive epidermotropic cytotoxic Tâ€cell lymphoma. British Journal of Haematology, 2021, 193, 9-9.	1.2	1
6	Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom realâ€world analysis of outcomes in 211 patients. British Journal of Haematology, 2021, 193, 290-298.	1.2	32
7	Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. British Journal of Haematology, 2021, 194, 365-377.	1.2	13
8	Interpretation of retrospective data evaluating highâ€dose methotrexate as central nervous system prophylaxis in diffuse large Bâ€cell lymphoma; caution required. American Journal of Hematology, 2021, 96, E338-E339.	2.0	5
9	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical Cancer Research, 2021, 27, 6323-6332.	3.2	42
10	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood Advances, 2020, 4, 3586-3593.	2.5	36
11	The prevention of central nervous system relapse in diffuse large B ell lymphoma: a British Society for Haematology good practice paper. British Journal of Haematology, 2020, 190, 708-714.	1.2	36
12	The investigation and management of follicular lymphoma. British Journal of Haematology, 2020, 191, 363-381.	1.2	14
13	Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. British Journal of Haematology, 2020, 190, 394-404.	1.2	27
14	Primary leptomeningeal Bâ \in cell lymphoma. British Journal of Haematology, 2019, 187, 412-412.	1.2	0
15	Frontline management of nodular lymphocyte predominant Hodgkin lymphoma – a retrospective UK multicentre study. British Journal of Haematology, 2019, 186, e214-e217.	1.2	9
16	Guidelines for the diagnosis and management of primary central nervous system diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2019, 184, 348-363.	1.2	104
17	Guideline for the management of mantle cell lymphoma. British Journal of Haematology, 2018, 182, 46-62.	1.2	38
18	A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma. British Journal of Haematology, 2018, 182, 63-70.	1.2	11

PAMELA MCKAY

#	Article	IF	CITATIONS
19	Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. British Journal of Haematology, 2016, 172, 32-43.	1.2	27
20	Guidelines for the management of diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2016, 174, 43-56.	1.2	125
21	Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. British Journal of Haematology, 2013, 163, 168-181.	1.2	50
22	Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network. Leukemia and Lymphoma, 2011, 52, 1920-1928.	0.6	26